Amylyx Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Amylyx Pharmaceuticals, Inc. (AMLX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$30.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$30.38M.
- Amylyx Pharmaceuticals, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$63.45M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$30.38M 10-K · filed 2026-03-03 |
| 2024-12-31 | -$63.45M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |